Novo Nordisk’s Pill and Medicare Double Act Fails to Silence Analyst Doubts
A dual catalyst – the UK launch of an oral version of Wegovy and a fresh US Medicare…
Novo Nordisk’s Hemophilia Breakthrough Fails to Distract From Canadian Generic Blow
Novo Nordisk’s stock slides 41% as Canada approves first generic Ozempic, while promising hemophilia data fails to lift…
Novo Nordisk’s Rare Disease Breakthrough Fails to Lift Oversold Shares
Novo Nordisk reports positive Phase 3 results for sickle cell drug etavopivat, but shares remain under pressure from…